Online inquiry

IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12435MR)

This product GTTS-WQ12435MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IFNG gene. The antibody can be applied in Hemophagocytic lymphohistiocytosis (HLH) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000619.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3458
UniProt ID P01579
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12435MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8031MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ9406MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ7336MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ8263MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ5746MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ15560MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ13380MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ12355MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA N63Ab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW